After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Conclusion. In the treatment of COPD exacerbations, systemic corticosteroids improve airflow limitations, decrease treatment failure rates, decrease the risk of relapse, and may improve symptoms ...

“Emphysema makes it hard to breathe air out of your lungs as it affects the tiny air sacs at the end of the airways where ...

Study identifies NMLR as a predictor of 5-year mortality in COPD patients, paving the way for personalised care and improved survival outcomes.

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

“Emphysema is part of a group of lung conditions which comes under the umbrella term chronic obstructive pulmonary disease ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Ohtuvayre showed significant improvement in lung function by 12 weeks. Follow-up analyses showed that Ohtuvayre had long-term ...